Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

SinoMab Bioscience, a Hong Kong Biotech, to IPO on Hong Kong Exchange

publication date: Jul 10, 2019

SinoMab Bioscience, a Hong Kong clinical-stage antibody company, reported its filing for a Hong Kong IPO has been accepted by the Exchange. Founded in 2001 by Dr. Shawn Leung, the company has two mAbs in clinical development against targets for autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus,) and cancer (non-Hodgkin’s lymphoma). It has another four mAbs in pre-clinical development. SinoMab claims particular expertise in hybridization technology for mAbs. Headquartered in Hong Kong, SinoMab has additional facilities in Shenzhen, Hainan and Suzhou. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital